Cell or Molecular Dysfunction

Nimbus Therapeutics Announces Leadership Transition: Abbas Kazimi Appointed as New CEO

2 months ago talkbio0Tagged Abbas Kazimi, Biotechnology, CEO, computational drug discovery, Nimbus, Transition Mutation

Nimbus Therapeutics, CEO transition, Abbas Kazimi, Jeb Keiper, biotechnology, computational drug discovery

Julie Kim to Succeed Christophe Weber as Takeda’s CEO in 2026

3 months ago talkbio0Tagged biopharmaceutical company, CEO, Christophe Weber, Drug Industry, Kim, Leadership, succession, Takeda, Transition Mutation

Takeda, Julie Kim, Christophe Weber, CEO succession, pharmaceutical industry, leadership transition, biopharmaceutical company

Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification

3 months ago talkbio0Tagged Alzheimer 's disease, Biogen, diversification, Immunology, Nerve Degeneration, Neuroscience discipline, Research Strategy

Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration

FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

5 months ago talkbio0Tagged Acute leukemia, Approved, Chromosomal translocation, KMT2A gene, Menin Inhibitor, Relapsing course, Revuforj, Syndax, United States Food and Drug Administration, Unresponsive to Treatment

FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals

FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment

7 months ago talkbio0Tagged Approved, HER2-negative, Hormones, Itovebi, Malignant neoplasm of breast, PI3 K inhibitor, PIK3CA Gene Mutation, receptor-positive, Roche (company), United States Food and Drug Administration

Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

7 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

7 months ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Metsera and Amneal Collaborate on Next-Generation Obesity Medicines, with Leadership Transition at Metsera

7 months ago talkbio0Tagged Amneal, Leadership, Manufacture, Metsera, Obesity, Partnership, strategic collaboration, Transition Mutation

Metsera, Amneal, Obesity Drugs, Strategic Collaboration, Manufacturing Partnership, Leadership Transition

Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology

9 months ago talkbio0Tagged biobucks, Eisai, molecular glue degraders, Neoplasms, Nerve Degeneration, Plant seeds

Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders

Anavex’s New Analysis of Alzheimer’s Pill Shows Mixed Results

9 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Anavex, Blarcamesine, Cerebral atrophy, EMA Approval, Mental deterioration, Nerve Degeneration, Phase IIb/III trial, Treatment Effectiveness

Anavex, Alzheimer’s disease, blarcamesine, Phase IIb/III trial, clinical efficacy, neurodegeneration, cognitive decline, amyloid-beta, brain atrophy, EMA approval.